{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:47:03Z","timestamp":1793227623836,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,27]]},"DOI":"10.7759\/cureus.46091","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T02:20:42Z","timestamp":1695867642000},"source":"Crossref","is-referenced-by-count":14,"title":["Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Hani Raka","family":"Karrar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Ismail","family":"Nouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef Ismail","family":"Nouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mawadah Ismaeel","family":"Nouh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel S","family":"Khan Alhindi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef Hassan","family":"Hemeq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Mohammed","family":"Aljameeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jameel Abdullah","family":"Aljuaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh Jabbar","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Abdulrahman","family":"Alsatami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona Ali","family":"Alkredees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman Olayan","family":"Almuqati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobhia N","family":"Abanmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal Mueidh","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.19","article-title":"Type 2 diabetes mellitus","volume":"1","author":"DeFronzo RA","year":"2015","unstructured":"DeFronzo RA, Ferrannini E, Groop L, et al.. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015, 1:15019. 10.1038\/nrdp.2015.19","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)60987-8","article-title":"Diabetes and hypertension: the bad companions","volume":"380","author":"Ferrannini E","year":"2012","unstructured":"Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012, 380:601-10. 10.1016\/s0140-6736(12)60987-8","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition","volume":"157","author":"Saeedi P","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P, et al.. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019, 157:107843. 10.1016\/j.diabres.2019.107843","journal-title":"Diabetes Res Clin Pract"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12787","article-title":"Does obesity cause type 2 diabetes mellitus (T2DM)? or is it the opposite?","volume":"20","author":"Malone JI","year":"2019","unstructured":"Malone JI, Hansen BC. Does obesity cause type 2 diabetes mellitus (T2DM)? or is it the opposite?. Pediatr Diabetes. 2019, 20:5-9. 10.1111\/pedi.12787","journal-title":"Pediatr Diabetes"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.12.068","article-title":"Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss","volume":"53","author":"Lavie CJ","year":"2009","unstructured":"Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009, 53:1925-32. 10.1016\/j.jacc.2008.12.068","journal-title":"J Am Coll Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the surpass clinical trials","volume":"12","author":"Min T","year":"2021","unstructured":"Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the surpass clinical trials. Diabetes Ther. 2021, 12:143-57. 10.1007\/s13300-020-00981-0","journal-title":"Diabetes Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023","volume":"46","author":"ElSayed NA","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al.. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care. 2023, 46:S140-57. 10.2337\/dc23-S009","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck MA","year":"2016","unstructured":"Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016, 4:525-36. 10.1016\/s2213-8587(15)00482-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S191438","article-title":"Dual GIP-GLP1-receptor agonists in the treatment of type 2 diabetes: a short review on emerging data and therapeutic potential","volume":"12","author":"Bastin M","year":"2019","unstructured":"Bastin M, Andreelli F. Dual GIP-GLP1-receptor agonists in the treatment of type 2 diabetes: a short review on emerging data and therapeutic potential. Diabetes Metab Syndr Obes. 2019, 12:1973-85. 10.2147\/DMSO.S191438","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3503","article-title":"The new dual gastric inhibitory peptide\/glucagon-like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?","volume":"37","author":"Papachristou S","year":"2021","unstructured":"Papachristou S, Popovic DS, Papanas N. The new dual gastric inhibitory peptide\/glucagon-like peptide 1 agonist tirzepatide in type 2 diabetes: Is the future bright?. Diabetes Metab Res Rev. 2021, 37:e3503. 10.1002\/dmrr.3503","journal-title":"Diabetes Metab Res Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas MK","year":"2021","unstructured":"Thomas MK, Nikooienejad A, Bray R, et al.. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021, 106:388-96. 10.1210\/clinem\/dgaa863","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis","volume":"65","author":"Karagiannis T","year":"2022","unstructured":"Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E. Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022, 65:1251-61. 10.1007\/s00125-022-05715-4","journal-title":"Diabetologia"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2023.05.012","article-title":"Tirzepatide and potential use for metabolically healthy obesity","volume":"113","author":"Copur S","year":"2023","unstructured":"Copur S, Tanriover C, Yavuz F, Tuttle KR, Kanbay M. Tirzepatide and potential use for metabolically healthy obesity. Eur J Intern Med. 2023, 113:1-5. 10.1016\/j.ejim.2023.05.012","journal-title":"Eur J Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar N","year":"2022","unstructured":"Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, Zoungas S. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022, 28:591-8. 10.1038\/s41591-022-01707-4","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.3.276","article-title":"Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States","volume":"29","author":"Zhang X","year":"2023","unstructured":"Zhang X, McAdam Marx C. Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States. J Manag Care Spec Pharm. 2023, 29:276-84. 10.18553\/jmcp.2023.29.3.276","journal-title":"J Manag Care Spec Pharm"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2337\/cd22-0029","article-title":"Efficacy and safety of tirzepatide in adults with type 2 diabetes: a perspective for primary care providers","volume":"41","author":"Kushner P","year":"2023","unstructured":"Kushner P, Anderson JE, Simon J, Boye KS, Ranta K, Torcello-G\u00f3mez A, Levine JA. Efficacy and safety of tirzepatide in adults with type 2 diabetes: a perspective for primary care providers. Clin Diabetes. 2023, 41:258-72. 10.2337\/cd22-0029","journal-title":"Clin Diabetes"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15647","article-title":"Glucagon-like peptide-1 in diabetes care: can glycaemic control be achieved without nausea and vomiting?","volume":"179","author":"Borner T","year":"2022","unstructured":"Borner T, Tinsley IC, Doyle RP, Hayes MR, De Jonghe BC. Glucagon-like peptide-1 in diabetes care: can glycaemic control be achieved without nausea and vomiting?. Br J Pharmacol. 2022, 179:542-56. 10.1111\/bph.15647","journal-title":"Br J Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS- 1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock J","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, et al.. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS- 1): a double-blind, randomised, phase 3 trial. Lancet. 2021, 398:143-55. 10.1016\/s0140-6736(21)01324-6","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ebd.6400504","article-title":"Benchmarking of reported search and selection methods of systematic reviews by dental speciality","volume":"8","author":"Major MP","year":"2007","unstructured":"Major MP, Major PW, Flores-Mir C. Benchmarking of reported search and selection methods of systematic reviews by dental speciality. Evid Based Dent. 2007, 8:66-70. 10.1038\/sj.ebd.6400504","journal-title":"Evid Based Dent"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.14573\/altex.1902131","article-title":"Software tools for literature screening in systematic reviews in biomedical research","volume":"36","author":"Van der Mierden S","year":"2019","unstructured":"Van der Mierden S, Tsaioun K, Bleich A, Leenaars CH. Software tools for literature screening in systematic reviews in biomedical research. ALTEX. 2019, 36:508-17. 10.14573\/altex.1902131","journal-title":"ALTEX"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the surpass-5 randomized clinical trial","volume":"327","author":"Dahl D","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodr\u00edguez \u00c1. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the surpass-5 randomized clinical trial. JAMA. 2022, 327:534-45. 10.1001\/jama.2022.0078","journal-title":"JAMA"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas JP","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021, 385:503-15. 10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS- 3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik B","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, et al.. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS- 3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021, 398:583-98. 10.1016\/s0140-6736(21)01443-4","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13979","article-title":"Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens","volume":"22","author":"Frias JP","year":"2020","unstructured":"Frias JP, Nauck MA, Van J, et al.. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020, 22:938-46. 10.1111\/dom.13979","journal-title":"Diabetes Obes Metab"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias JP","year":"2018","unstructured":"Frias JP, Nauck MA, Van J, et al.. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018, 392:2180-93. 10.1016\/s0140-6736(18)32260-8","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/170540-tirzepatide-induced-gastrointestinal-manifestations-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:07:04Z","timestamp":1707509224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/170540-tirzepatide-induced-gastrointestinal-manifestations-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.46091","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}